1.65
+400.45%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alps Group
Its shares trade under the ticker ALPS. It has been listed since 31 October 2025.
Alps Group Inc is a MY-based company operating in industry. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 31 Oct 2025
- Employees
- 89
- Head office
- UNIT E-18-01 & E-18-02, LEVEL 18,, KUALA LUMPUR
- Incorporated in
- E9
- Classification
- Services-Health Services
- Filer status
- Non-accelerated filer<br>Emerging growth company
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alps Life Sciences Inc. integrates R&D, medical services, and wellness solutions under one ecosystem.
- The company cultivates a diverse pipeline including MyImmune (NK cells) and CAR-T cell therapies.
- Alps Group Inc. operates a molecular laboratory and cGMP cell and gene therapy research facility.
Weaknesses
- The company has only 89 employees, which may limit operational capacity.
- Alps Group Inc. is listed on 31 October 2025, a recent IPO with limited market history.
- The company operates solely in Malaysia, restricting global market reach.
Opportunities
- Expanding MyImmune (NK cells) and CAR-T cell therapies into international markets.
- Growing demand for diabetes therapeutics and stem cell technologies like iPSCs.
- Increasing global interest in mRNA platform technology for vaccines and treatments.
Threats
- Competition from established biotechnology firms in the global market.
- Regulatory challenges in the healthcare sector affecting new therapies.
- Economic downturns impacting investment in biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.